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ABSTRACT 
 
Rationale, aims and objective: 
We previously demonstrated that annual review %FEV1 under-estimates lung health of adults with 
CF compared to %FEV1 captured during periods of clinical stability. This has implications in the 
comparisons against registries with encounter-based FEV1, such as the US. It is uncertain whether 
this bias affects between-centre comparison within the UK. Previous funnel plot analyses have 
identified variation in annual review %FEV1 according to centre size, hence we investigated 
whether paired differences between annual review and best %FEV1 also vary according to centre 
size. 
 
Methods: 
This registry analysis included 18 adult CF centres in the UK with ≥80% completeness for best 
FEV1 data in 2014. Mean discrepancy between annual review and best %FEV1 is a surrogate for 
the extent by which annual review %FEV1 underestimates lung health; and was plotted against 
centre size. A Local Polynomial Regression (LOESS) curve was used to explore the relationship 
between the two variables. An appropriate model is fitted based on the LOESS curve to determine 
the strength of relationship between discrepancies in %FEV1 and centre size. 
 
Results: 
There is an inverted U-shaped relationship between mean discrepancies in %FEV1 and centre 
size. A regression of the paired mean difference in %FEV1 against centre size showed a significant 
improvement in the goodness of fit for a quadratic model (R2 = 23.8% for a quadratic model 
compared with 0.4% for a linear one; p = 0.048 for the quadratic term).  
 
Conclusions: 
Annual review %FEV1 under-estimated lung health of adults from small and large centres in the UK 
to a greater extent compared to medium-sized centres. A plot of %FEV1 against centre size (e.g. 
funnel plot comparison) would be affected by systematic bias in annual review %FEV1. Therefore, 
annual review %FEV1 is an unreliable metric to compare health outcomes of adult CF centres 
within the UK. 
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INTRODUCTION 
 
Cystic fibrosis (CF) is an archetypal long-term health condition – it is progressive and life-limiting 
with no cure at present, but an array of effective medications is available to improve prognosis. 
Median CF survival is currently 45-50 years, compared to survival of around 6 months in the 
1940’s.1,2 This dramatic improvement is partly due to increasing numbers of efficacious therapeutic 
options.3 However, improvement in the quality of care provided by specialist CF centres is also 
crucial.4 Indeed, quality improvement initiatives e.g. centre-comparisons and benchmarking have 
been critical in transforming healthcare delivery in CF.5-8  
 
The UK CF registry annual data report plots centre-level %FEV1 as a ranked graph (caterpillar plot) 
and also as a funnel plot, with the aim of using data to drive quality improvement.9 In a funnel plot, 
the outcome of interest is plotted against centre size with control limits narrowing as the centre size 
increases.10 Centres that lie outside the control limits of a funnel plot arguably have outcomes that 
reflect a genuine difference from the average, i.e. a funnel plot implies that centres lying outside 
the control limits are ‘better’ or ‘worse’ than expected.10 
 
Annual review %FEV1 has traditionally been used as the %FEV1 metric for comparing centres in 
the UK CF registry annual data report.11 Recently a greater emphasis has been placed on best 
FEV1 and this allows us to explore the differences between the two metrics. Previous funnel plot 
analyses have identified an inverted U-shape relationship between annual review %FEV1 and 
centre size, with negative outliers tended to be smaller (<100 adults) and larger (>350 adults) 
centres instead of medium-sized centres.12 Taken at face value, this might imply that medium-
sized adult CF centres in the UK achieved the best health outcomes and standards of care.  
 
However, the ‘pyramid of investigation’ model emphasises that data must first be sufficiently robust 
before drawing other conclusions (e.g. regarding quality of care) in observational epidemiology.13 
Our previous analysis demonstrated that annual review %FEV1 underestimates lung health of 
adults with CF in the UK in comparison to %FEV1 captured during periods of clinical stability.14 It is 
uncertain whether the bias in annual review %FEV1 affects between-centre comparison within the 
UK. It may be that annual review %FEV1 under-estimates centre-level lung health for all adult CF 
centre by the same extent because procedures pertaining to annual review could be identical in all 
centres. Alternatively, the bias in annual review %FEV1 may differ between different centres such 
that between-centre comparisons within the UK are also affected.  
 
We investigated this issue using data from the UK CF registry to determine whether discrepancies 
between annual review %FEV1 and best annual %FEV1 vary according to centre size and thus 
affect between-centre comparisons using a funnel plot analysis. 
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METHODS AND MATERIALS 
 
This is a cross-sectional analysis using the UK CF registry data for 2014 from 18 UK adult CF centres 
with ≥80% completeness for best FEV1 data. Ten centres with <80% completeness for best FEV1 data 
were excluded because comparison between annual review and best %FEV1 are less reliable with 
large amount of missing best FEV1 data. Adults who had a lung transplantation were also excluded 
because lung transplantation has transformative effects on lung health,15 such that their FEV1 no 
longer represent that of a typical adult with CF. NHS research ethics approval (Huntingdon Research 
Ethics Committee 07/Q0104/2) was granted for the UK CF Registry. Under the terms of the NHS 
ethics approval, the UK CF Trust steering committee approved this study. 
 
The UK CF registry data were collected during annual reviews between 1st January and 31st 
December 2014. Data for age, gender, pancreatic status, CF related diabetes and body mass index 
(BMI, in kg/m2) were obtained to understand the demographics of the participants included in this 
analysis. Annual review FEV1 data were the FEV1 readings taken during annual review. In addition to 
annual review FEV1 data, best FEV1 data have been collected by the UK CF registry since 2012 for 
the European CF Society Patient registry.16 The best FEV1 data represent the highest FEV1 reading in 
the 1-year period prior to the date of annual review (i.e. if a person had annual review on 1st July 
2014, the highest FEV1 reading between 1st July 2013 to 1st July 2014 should be that person’s ‘best 
FEV1’ for 2014). Both the annual review and best %FEV1 were calculated using Knudson equation.17  
 
The magnitude of group-level mean discrepancy between paired annual review and best %FEV1 is a 
surrogate for the extent by which annual review %FEV1 underestimates lung health of adults with CF 
– a larger discrepancy indicates greater underestimation of centre-level lung health and vice versa.14 
Therefore, centre-by-centre discrepancy between paired annual review and best %FEV1 were 
calculated, then plotted against centre size. A Local Polynomial Regression (LOESS) curve was used 
to explore the relationship between centre-level mean discrepancy in %FEV1 and centre size. The 
LOESS curve was generated using default SPSS v24.0 setting (Kernel: Epanechnikov, 50% of points 
to fit). LOESS curve is a non-parametric method for fitting smooth curves to data, to depict 
relationships between variables.18 An appropriate parametric model was then fitted based on the 
relationship depicted by the LOESS curve, to determine the strength of relationship between centre-
level discrepancies in %FEV1 vs centre size. Centre-level annual review %FEV1 adjusted for age and 
pancreatic status (to account for differences in case-mix between centres) was also plotted on a 
funnel plot for all 28 adult CF centres. This allows identification of positive and negative outliers, 
elucidation of the relationship between centre-level annual review %FEV1 vs centre size, and 
comparison with the plot of centre-level discrepancies in %FEV1 vs centre size. 
  
The following sensitivity analyses to further understand the relationship between centre-level 
discrepancies in %FEV1 vs centre size were also reported in the online appendix: LOESS curve fitted 
through 25% and 75% of points, LOESS curve and the parametric model fitted after excluding the 
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extreme left and extreme right points on the scatterplot, weighted analysis for the parametric model, 
analyses repeated using paired median difference in %FEV1 (instead of mean difference) and 
analyses repeated with centre size truncated at 150 (i.e. around 150 adults were randomly sampled in 
centres with more than 150 adults). Analyses were performed using SPSS v24 (IBM Corp, Armonk, 
NY, USA), Stata 14 (StatCorp, College Station, TX, USA) and R v3.3.0 (R Foundation for Statistical 
Computing, Vienna, Austria). A p-value <0.05 was considered to be statistically significant. 
 
 
RESULTS 
 
In total, there were 4925 adults without lung transplantation across 28 adult CF centres in the UK. Of 
these, 3149 (63.9%) were from the 18 centres with ≥80% completeness for best FEV1 data in 2014. 
Of the 15 medium-sized centres (100–350 adults), 12 (80%) had ≥80% completeness for best FEV1 
data, whereas this level was only achieved by 5 (50%) of the 10 smaller centres (<100 adults) and by 
1 (33%) of the 3 larger centres (>350 adults). Adults from centres with either ≥80% or <80% 
completeness for best FEV1 data were similar in terms of gender, pancreatic status and CF related 
diabetes (see Table 1). Adults from centres with ≥80% completeness for best FEV1 data were slightly 
younger (median age 27 years vs 29 years), which may partly explain the slightly higher annual 
review %FEV1 for that group (median 67.6% vs 64.4%).  
 
After adjusting for age and pancreatic status using a generalised linear model (GLM) approach as 
previously described,19 a funnel plot analysis for all 28 adult CF centres in the UK with annual review 
%FEV1 as the outcome of interest identified six centres (four of which had <100 adults, two of which 
had >350 adults) as negative outliers (i.e. lower than expected %FEV1) and one centre with 100–350 
adults as a positive outlier (i.e. higher than expected %FEV1), see Figure 1a. The LOESS curve of 
%FEV1 versus centre size showed an inverted U-shaped relationship between case-mix adjusted 
annual review %FEV1 and centre size (Figure 1b). A regression of the %FEV1 against centre size 
showed a significant improvement in the goodness of fit for a quadratic model (R2 = 28.8% for a 
quadratic model compared with 10.5% for a linear one; p = 0.018 for the quadratic term). The 
quadratic model is y = b0 + b1x +b2x2 where y = case-mix adjusted annual review %FEV1, x = number 
of adults in each centre. 
 
Among the 18 centres with ≥80% completeness for best FEV1 data, there was also an inverted U-
shaped relationship between centre-level paired mean difference in %FEV1 and centre size (see 
Figure 2). A regression of the paired mean difference in %FEV1 against centre size showed a 
significant improvement in the goodness of fit for a quadratic model (R2 = 23.8% for a quadratic model 
compared with 0.4% for a linear one; p = 0.048 for the quadratic term). After excluding the extreme 
left and extreme right points on the scatterplot, similar results were obtained (R2 = 30.0% for a 
quadratic model compared with 0.7% for a linear one; p = 0.036 for the quadratic term), see Appendix 
B. Broadly similar results were also obtained with other sensitivity analyses detailed in Appendices A-
E.
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Given that the magnitude of group-level mean discrepancy between paired annual review and best 
%FEV1 is a surrogate for the extent by which annual review %FEV1 underestimates lung health, this 
finding suggests that annual review %FEV1 underestimates lung health to a greater extent in smaller 
and larger centres. Therefore, the relationship observed in a funnel plot analysis among adult CF 
centres within the UK with annual review %FEV1 as the outcome of interest may well be exaggerated 
by the systematic bias in annual review FEV1 data.  
 
 
DISCUSSION 
 
We previously demonstrated that annual review %FEV1 under-estimates lung health of adults in 
comparison to %FEV1 captured during periods of clinical stability, which is an important systematic 
bias to consider for cross-country comparisons against registries with encounter-based FEV1.14 In this 
manuscript, we extended our previous work and analysed centre-by-centre discrepancy between 
paired annual review and best %FEV1 to determine if systematic bias in annual review FEV1 also 
affects between-centre comparisons within the UK. We found a statistically significant quadratic 
relationship between centre-level paired mean difference in %FEV1 and centre size. This mirrored the 
relationship between case-mix adjusted annual review %FEV1 and centre size in a funnel plot 
analysis; implying that systematic bias in annual review %FEV1 according to centre size exaggerates 
the relationship observed in the funnel plot. As such, annual review %FEV1 is an unreliable metric to 
compare health outcomes of adult CF centres within the UK using a funnel plot. Other forms of UK CF 
registry comparisons using annual review %FEV1 as the outcome of interest may also be affected by 
systematic bias. 
 
Our findings emphasise the importance of data issues for accurate and reliable interpretations of 
results from CF registry comparisons. Registry comparisons are only meaningful if apples are being 
compared to apples and not to oranges because systematic bias in registry data cannot be easily 
controlled with statistical methods,20 even for objective outcomes e.g. survival.21 Indeed, the ‘pyramid 
of investigation’ model advocates an incremental approach to understand variation in health 
outcomes, starting with review of data before considering other potential sources of variation e.g. 
differences in case-mix and quality of care.13 Using annual review %FEV1 as a metric to infer lung 
health, it would appear as though adults at medium-sized adult CF centres (i.e. centres with 100–350 
adults) have better lung health compared to adults in smaller (<100 adults) or larger (>350 adults) 
centres in the UK. We suggest that smaller and larger centres may simply have greater difficult in 
organising annual reviews during periods of clinical stability, hence underestimating the lung health of 
their population. Certainly for very large centres with a busy annual review schedule (a centre with 
600 adults would need to complete an average of more than 11 annual reviews per week), there is 
less flexibility for re-scheduling another annual review prior to the data entry deadline if an adult were 
to turn up unwell. 
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Our findings may also explain some of the results in a recent UK CF registry analysis by Nightingale 
and Osmond.9 In that analysis, centre ranking based on annual review %FEV1 varied substantially 
from year-to-year. Centre ranking based on annual review %FEV1 was also substantially different 
from centre ranking based on change in annual review %FEV1. Since standard of care provided by an 
adult CF centre is unlikely to change rapidly from year-to-year, and similar rankings should be 
achieved with both FEV1 and change in FEV1 if both metrics are reliable measures of lung health for 
adults with CF, Nightingale and Osmond surmised that any apparent FEV1 difference is unlikely to be 
related to differing standards of care between centres.9 In light of our finding that annual review FEV1 
in the UK were not always collected during periods of clinical stability (i.e. lung health is being 
measured with error by annual review FEV1), the year-to-year variation in centre ranking and 
discrepancies between FEV1 and change in FEV1 may be related at least in part to the inherent bias 
of annual review FEV1. The main driver for FEV1 fluctuation is pulmonary exacerbation,22 which is a 
stochastic event.23 An adult who turned up during annual review at Year 1 with an exacerbation may 
be well during annual review at Year 2. The increased variability of annual review FEV1 from year-to-
year (compared to “FEV1 when stable”) means that centre ranking based on annual review FEV1 
would be more prone to fluctuation compared to centre ranking based on “FEV1 when stable”. The 
increased variability of annual review FEV1 from year-to-year (compared to “FEV1 when stable”) also 
means that the calculated change in FEV1 in an unreliable metric for lung health – a large decline in 
annual review FEV1 may simply be due to transient pulmonary exacerbation instead of representing a 
substantial drop in actual lung health. This would explain the discrepancies in centre ranking based 
on FEV1 and change in FEV1. In other words, it is not that “FEV1 when stable” is an unreliable metric 
to infer standards of care for adult CF centres in the UK; but annual review FEV1 with its inherent bias 
is an unsuitable metric for centre comparison.  
 
Therefore, it is unnecessary to abandon the use of FEV1 as a metric for centre comparisons or 
benchmarking in the UK. However, it is crucial to use a more reliable metric than annual review FEV1 
to accurately reflect lung health. There is currently a two tier data collection system within the UK CF 
registry. Encounter-based data collection is mandatory for the minority of people with CF that 
participate in registry-based trials such as CF START (ISRCTN18130649). However, data are only 
collected from the vast majority of people with CF on an annual basis (during annual reviews). There 
has been a move by the UK CF registry towards comparisons using best FEV1 data (which may be 
more reliable than annual review FEV1); and it is encouraging that in the 2017 registry annual data 
report 25/28 (89%) of centres now have ≥80% completeness for best FEV1 data.24 Nonetheless, “best 
FEV1” reported to the registry could still under-estimate the lung health of people with CF if these data 
did not reliably select the highest FEV1 from all FEV1 readings over a 1-year period.14 Identification of 
best FEV1 data is difficult if data collectors are required to manually extract these data from routine 
clinical record, particularly in larger centres.  
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Indeed, best FEV1 data are most robust if all FEV1 readings are recorded in a single database via 
encounter-based data collection, such that the highest reading over a given time period can be 
automatically and accurately identified. Other than supporting reliable centre comparison using FEV1 
and driving iterative quality improvement cycles, encounter-based data collection for all study subjects 
(e.g. the US CFFPR25) also has other benefits, including allowing robust study of FEV1 decline 
trajectory and impact of FEV1 variability.22 There are concerns regarding the resource requirements to 
implement comprehensive encounter-based data collection; but a previous modelling exercise using 
worst case scenario estimates did suggest that 75 minutes of data entry session per week would be 
adequate for a medium-sized CF centre to implement this, which is equivalent to a cost of 
approximately £4 per patient per year.26 Some adult CF centres in the UK, such as Leeds and 
Sheffield, have already implemented encounter-based FEV1 data collection via the use of integrated 
electronic care records;27,28 and the CFHealthHub platform (ISRCTN55504164) now in use in 80% of 
the UK adult CF centres also offers a facility for encounter-based FEV1 data capture. 
 
The %FEV1 in this analysis was calculated using Knudson equation to mirror the approach of our 
previous work.14 Similar results for the discrepancy between annual review and best %FEV1 would be 
obtained with GLI equation because paired difference between two FEV1 readings was calculated.29 A 
limitation of our analysis is data on the number of FEV1 readings per patient are unavailable due to 
the lack of encounter-based data entry in the UK CF registry. It may be possible that medium-sized 
centres were able to review their patients more frequently and to perform more FEV1 measurements 
per patient (i.e. have a better chance of identifying the ‘true’ best FEV1 reading). Having the data on 
FEV1 readings per patient could therefore provide further evidence to support our hypothesis that 
there is differential data collection by UK adult CF centres according to centre size. It is more likely for 
larger centres to under-estimate their best FEV1 compared to medium-sized centres. Thus our 
findings that larger centres have larger paired FEV1 differences would be even more obvious if larger 
centres were not under-estimating their best FEV1. Another limitation is the extent of missing best 
FEV1 data in the UK CF registry. It is also uncertain whether similar findings exist in other years. This 
analysis was limited to 2014 because best FEV1 data were only being collected from 2012 onwards, 
and best FEV1 data were only available for 780/4380 (17.8%) and 1004/4528 (22.3%) of the adults in 
2012 and 2013 respectively. Repeating the analysis using the 2016 and 2017 datasets would help to 
confirm our findings. 
 
Nonetheless, there is other circumstantial evidence to indicate differential data collection by UK adult 
CF centres according to centre size. Firstly, medium-sized adult CF centres (i.e. centres with 100–350 
adults) were more likely to achieve ≥80% completeness for best FEV1 data (12/15, 80%) compared to 
smaller centres (<100 adults; 5/10, 50%) and larger centres (>350 adults; 1/3, 33%). Secondly, 
centres with <80% completeness for best FEV1 data were twice as likely to report missing pancreatic 
status compared to centres with ≥80% completeness for best FEV1 data (24/1776, 1.4% vs 23/3149, 
0.7%).  
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FEV1 is often used as an outcome measure for benchmarking exercises in CF5,8,30,31 since it is an 
important CF prognostic marker.32-35 This is the first study to demonstrate empirically the systematic 
bias in annual review FEV1 according to CF centre size and its unsuitability as a metric to compare 
health outcomes of adult CF centres within the UK. In order to reliably discern the quality of CF 
centres in the UK, the UK CF registry data collection system may require modification.  
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Table 1: Characteristics of adults with CF from UK centres with ≥80% and <80% completeness for 
best FEV1 data 
 
 
 
 
 
 
 
2014 UK CF registry data 
among adult CF centres  
with ≥80% completeness  
for best FEV1 data § 
 
2014 UK CF registry data 
among adult CF centres  
with <80% completeness  
for best FEV1 data Ω 
 
Total number of adults, N 
 
Number of adults per centres  
        Median (IQR) 
        Mean (95% CI) 
 
Total number of adult CF centres, N 
 
Number of centres according to size 
        <100 adults, N (%) 
        100–350 adults, N (%) 
        >350 adults, N (%) 
 
 
3149 
 
 
186 (75 – 241) 
175 (128 – 222) 
 
18 
 
 
5 (27.8) 
12 (66.7) 
1 (5.6) 
 
1776 
 
 
111 (53 – 248) 
178 (52 – 303) 
 
10 
 
 
5 (50.0) 
3 (30.0) 
2 (20.0) 
 
Characteristics of adults: 
 
Age in years, median (IQR) 
 
Female, N (%) 
 
Pancreatic insufficient,† N (%) 
 
CF related diabetes, N (%) 
 
BMI in kg/m2, median (IQR) 
 
Annual review %FEV1,‡ median (IQR) 
 
Best %FEV1,‡ median (IQR) 
 
 
 
 
 
27 (22 – 35) 
 
1422 (45.2) 
 
2582 (82.6) a 
 
1030 (32.7) 
 
22.2 (20.2 – 24.8) 
 
67.6 (46.9 – 86.0) 
 
73.2 (53.5 – 91.0) c 
 
 
 
 
29 (23 – 37) 
 
803 (45.2) 
 
1427 (81.4) b 
 
572 (32.2) 
 
22.1 (19.8 – 24.5) 
 
64.4 (44.3 – 84.2) 
 
69.2 (47.9 – 89.6) d 
 
§
 These centres were included in the analyses to determine the centre-by-centre discrepancy between paired 
annual review and best %FEV1. 
 
Ω
 These centres were excluded from the analyses to determine the centre-by-centre discrepancy between 
paired annual review and best %FEV1 due to the extent of missing best %FEV1 data. 
 
†
 Data for pancreatic replacement therapy (PERT) use were obtained. People on PERT were considered 
‘pancreatic insufficient’. People not on PERT were considered ‘pancreatic sufficient’. PERT use documented as 
‘unknown’ is considered as missing data. 
 
‡
 % predicted FEV1 was calculated using the Knudson equation. 
 
a
 Pancreatic status was missing for 23 (0.7%) of the adults in centres with ≥80% completeness for best FEV1 
data. 
 
b
 Pancreatic status was missing for 24 (1.4%) of the adults in centres with <80% completeness for best FEV1 
data. 
 
c
 Best FEV1 data was available for 2780 (88.3%) of the adults in centres with ≥80% completeness for best FEV1 
data. 
 
d
 Best FEV1 data was available for 427 (24.0%) of the adults in centres with <80% completeness for best FEV1 
data. 
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Figure 1: A funnel plot and a graph showing the age and pancreatic status adjusted annual review %FEV1 according to CF centre size in 2014 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Centres 1, 6, 7, 10, 11 and 26 are negative outliers, i.e. these 
centres appear to have ‘lower than expected’ levels of annual 
review %FEV1  
Number 
of adults 
in each 
centre 
Median age & pancreatic status 
adjusted annual review %FEV1  
Median age & pancreatic status 
adjusted annual review %FEV1  
Figure 1a: Funnel plot Figure 1b: Graph with a LOESS curve 
These six centres are 
identified as negative 
outliers in the funnel plot 
 
A quadratic line 
 
Centre 19 is a positive outliers, i.e. this centre 
appears to have a ‘higher than expected’ level 
of annual review %FEV1  
LOESS curve shows an inverted U-
shape relationship between age and 
pancreatic status adjusted annual 
review %FEV1 and centre size 
 
Number of adults  
in each centre 
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Figure 2: Graph showing the centre-level paired mean difference between annual review and best %FEV1 according 
to the size of CF centres in 2014 (only data from centres with ≥80% data completeness for best FEV1 included) 
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